Bovie Medical Corporation Announces FDA 510(K) Clearance To Market SEER Tissue Resection Device

Main Category: Liver Disease / Hepatitis
Also Included In: Cancer / Oncology
Article Date: 20 Nov 2008 - 9:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Bovie Medical Corporation (the "Company") (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company received 510(k) clearance from the Food and Drug Administration (FDA) to market its SEER tissue resection device intended for initial use in liver oncology surgery. The SEER device uses conductive sintered steel as an electrode for radio frequency (RF) for cutting and coagulation.

The process involves delivery of RF current and sterile saline for resection and coagulation in surgical procedures. The Company anticipates developing additional products based on the SEER technology for use in orthopedic and blood vessel sealing procedures. The worldwide market size for the liver and orthopedic market is expected to total $500 million in 2009.

Andrew Makrides, president of Bovie stated, "We are pleased to have received FDA 510(k) clearance to market the SEER device in the United States having already CE Marked the product for sale in the European Union. Bovie's ability to market the SEER positions the Company closer to its goal of increasing shareholder value through the development of proprietary technologies and products."

For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie's website http://www.boviemedical.com.

This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company's SEC filings.

Bovie Medical Corporation